Antiepileptic drug-induced neuronal cell death in the immature brain: Effects of carbamazepine, topiramate, and levetiracetam as monotherapy versus polytherapy

被引:101
作者
Kim, Jinsook
Kondratyev, Alexei
Gale, Karen
机构
[1] Georgetown Univ, Interdisciplinary Program Neurosci, Med Ctr, Washington, DC 20057 USA
[2] Georgetown Univ, Dept Pharmacol, Med Ctr, Washington, DC 20057 USA
[3] Georgetown Univ, Dept Pediat, Med Ctr, Washington, DC 20057 USA
关键词
D O I
10.1124/jpet.107.126250
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this study was to test the potential neurotoxicity of three antiepileptic drugs (AEDs), carbamazepine (5H-dibenzepine-5-carboxamide), topiramate [2,3: 4,5-bis-O-(1-methylethylidene)beta- D- fructopyranose sulfamate], and levetiracetam [2-(2-oxopyrrolidin-1-yl)butanamide], in the developing rat brain, when given alone or in combinations. The extent of cell death induced by AEDs was measured in several brain regions of rat pups ( postnatal day 8) by terminal deoxynucleotidyl transferase dUTP nick-end labeling assay 24 h after drug treatment. Carbamazepine alone did not increase neurodegeneration when given in doses up to 50 mg/kg, but it induced significant cell death at 100 mg/kg. When combined with phenytoin, carbamazepine, 50 but not 25 mg/kg, significantly exacerbated phenytoin-induced cell death. Although topiramate (20-80 mg/kg) alone caused no neurodegeneration, all doses exacerbated phenytoin-induced neurodegeneration. Levetiracetam (250-1000 mg/kg) alone did not induce cell death, nor did it exacerbate phenytoin-induced neurodegeneration. Of the combinations examined, only that of levetiracetam (250 mg/kg) with carbamazepine (50 mg/kg) did not induce neurodegeneration. Our data underscore the importance of evaluating the safety of combinations of AEDs given during development and not merely extrapolating from the effects of exposure to single drugs. Although carbamazepine and topiramate alone did not induce neuronal death, both drugs exacerbated phenytoin-induced cell death. In contrast, because cotreatment with levetiracetam and carbamazepine did not enhance cell death in the developing brain, it may be possible to avoid proapoptotic effects, even in polytherapy, by choosing appropriate drugs. The latter drugs, as monotherapy or in combination, may be promising candidates for the treatment of women during pregnancy and for preterm and neonatal infants.
引用
收藏
页码:165 / 173
页数:9
相关论文
共 40 条
[1]  
ADAB N, 2004, COCHRANE DATABASE SY
[2]   Antiepileptic drugs and apoptotic neurodegeneration in the developing brain [J].
Bittigau, P ;
Sifringer, M ;
Genz, K ;
Reith, E ;
Pospischil, D ;
Govindarajalu, S ;
Dzietko, M ;
Pesditschek, S ;
Mai, I ;
Dikranian, K ;
Olney, JW ;
Ikonomidou, C .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (23) :15089-15094
[3]   THE NONCOMPETITIVE AMPA/KAINATE RECEPTOR ANTAGONIST, GYKI-52466, POTENTIATES THE ANTICONVULSANT ACTIVITY OF CONVENTIONAL ANTIEPILEPTICS [J].
BOROWICZ, KK ;
GASIOR, M ;
KLEINROK, Z ;
CZUCZWAR, SJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 281 (03) :319-326
[4]   Effect of topiramate following recurrent and prolonged seizures during early development [J].
Cha, BH ;
Silveira, DC ;
Liu, XZ ;
Hu, YC ;
Holmes, GL .
EPILEPSY RESEARCH, 2002, 51 (03) :217-232
[5]   Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy [J].
Coppola, G ;
Mangano, S ;
Tortorella, G ;
Pelliccia, A ;
Fels, A ;
Romano, A ;
Nardello, R ;
Habetswallner, F ;
Licciardi, F ;
Operto, FF ;
Pascotto, A .
EPILEPSY RESEARCH, 2004, 59 (01) :35-42
[6]  
FARBER NB, 2005, 2005 ASTR VIEW IT PL
[7]   Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4-to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate [J].
Fountain, Nathan B. ;
Conry, Joan A. ;
Rodriguez-Leyva, Ildefonso ;
Gutierrez-Moctemma, Juvenal ;
Salas, Edubijes ;
Coupez, Rene ;
Stockis, Armel ;
Lu, Zhihong .
EPILEPSY RESEARCH, 2007, 74 (01) :60-69
[8]   Topiramate pharmacokinetics in infants [J].
Glauser, TA ;
Miles, MV ;
Tang, P ;
Clark, P ;
McGee, K ;
Doose, DR .
EPILEPSIA, 1999, 40 (06) :788-791
[9]  
Glauser Tracy A, 2004, J Child Neurol, V19 Suppl 1, pS25
[10]   Therapeutic doses of topiramate are not toxic to the developing rat brain [J].
Glier, C ;
Dzietko, M ;
Bittigau, P ;
Jarosz, B ;
Korobowicz, E ;
Ikonomidou, C .
EXPERIMENTAL NEUROLOGY, 2004, 187 (02) :403-409